Halo Genomics will work in partnership with Cambio Ltd. to introduce the Selector product line for targeted resequencing to the British market. Cambio Ltd is a privately held UK company, established over 25 years ago, with an excellent reputation for the supply of quality molecular biology reagents and consumables for the life science market.
Commenting on the agreement, Maria Hjortsmark, Chief Business Officer said, “UK is an important market for us, so it was vital that we found the right partner. Cambio has the technical expertise to provide high quality product support to next generation sequencing core facilities.”
Dr Peter Dean, Chairman of Cambio Ltd said, “Selector Target Enrichment Kit is an excellent addition to our current Next Generation Sequencing product portfolio. We are excited to bring this innovative technology to our market place”.
Halo Genomics is a provider of innovative technology for sample preparation in next generation sequencing. Halo Genomics was founded by scientists from Uppsala University and Olink AB. Based in Uppsala, Sweden, the company's solutions are offered to a wide range of academic, government, pharmaceutical, biotechnology, and other leading institutions around the world.